<DOC>
	<DOCNO>NCT01135524</DOCNO>
	<brief_summary>The purpose phase evaluate long-term safety tolerability BTDS . Qualified subject start BTDS 5 dose may titrate , necessary , maximum BTDS 20 achieve stable pain control .</brief_summary>
	<brief_title>Safety Buprenorphine Transdermal Patch ( BTDS ) Osteoarthritis Pain : 52-Week Extension Phase</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Subjects complete visit doubleblind phase study drug subject discontinue study drug due lack therapeutic effect doubleblind phase complete visit doubleblind phase study drug eligible enroll extension phase . Subjects prematurely discontinue study drug doubleblind phase due adverse event , subject 's choice , administrative reason lose followup NOT eligible enter extension phase Subjects electrocardiogram ( ECGs ) show QT data correct heart rate use Fridericia formula ( QTcF ) interval â‰¥ 500 millisecond ( msec ) discontinue extension phase . Subjects require longacting opioid analgesic ( twicedaily dose every ( q ) 24 hour ( h ) q12h drug ) transdermal fentanyl extension phase discontinue study . Refer core study additional inclusion/exclusion information .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Opioid</keyword>
	<keyword>Transdermal</keyword>
</DOC>